Cosmos Health vs DataMeds AI
COSM and MEDS side by side, both in wholesale trade-non-durable goods. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How COSM and MEDS compare
Cosmos Health is the larger company, worth 143 times as much as DataMeds AI ($326M against $2.3M).
Cosmos Health grew revenue faster over the last twelve months (33.8% versus −77.5% for DataMeds AI).
Cosmos Health keeps more of each dollar of sales as profit, with a net margin of −33.1% compared with −565% at DataMeds AI.
Cosmos Health scores higher on the StockData Score (4 against 1 for DataMeds AI), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | COSM | MEDS |
|---|---|---|
| Size and price | ||
| Market cap | $326M | $2.3M |
| Share price | $3.24 | $0.744 |
| Change, 1 year | −77.8% | −97.4% |
| Change, 5 years | −99.8% | – |
| Beta (5Y) | 5.79 | 0.17 |
| Employees | 163 | 35 |
| StockData Score | ||
| Total score | 4 (better) | 1 |
| Valuation score | 0 | 1 (better) |
| Growth score | 2 (better) | 0 |
| Performance score | 0 | 0 |
| Health score | 2 (better) | 0 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 4.4× | 0.3× (better) |
| P/B | 15.8× | – |
| FCF yield | −3.0% | – |
| Fair value | $1.38 | – |
| Margin of safety | −135% | – |
| Growth | ||
| Revenue growth (TTM) | 33.8% (better) | −77.5% |
| Revenue growth, 5Y average | 3.3% | – |
| Profitability | ||
| Gross margin | 10.3% (better) | −92.1% |
| Operating margin | −24.9% (better) | −548% |
| Net margin | −33.1% (better) | −565% |
| FCF margin | −13.5% | – |
| Return on equity | −104% (better) | −1707% |
| Return on invested capital | −60.9% (better) | −153% |
| Financial health | ||
| Debt / equity | 0.06 | – |
| Interest coverage | −7.8× | −6.2× (better) |
| Current ratio | 1.05 (better) | 0.14 |
| Altman Z-score | 1.81 (better) | −8.90 |
| Piotroski F-score | 5 (better) | 1 |
| Dividends and buybacks | ||
| Buyback yield | −2.6% | – |
| Shareholder yield | −2.6% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 2.1% | 1.7% |
| Held by insiders | 17.4% | – |
| Insider net buying, 12 months | $1.6M | – |
| Short interest, % of float | 2.1% | – |
Go deeper
- COSM stock overview
- COSM income statement
- COSM valuation and score
- MEDS stock overview
- MEDS income statement
- MEDS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.